Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbralisib and Rituximab in FL and MZL
NCT03919175Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2019
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of umbralisib in follicular lymphoma (FL) and marginal zone lymphoma (MZL), sponsored by Massachusetts General Hospital. Primary endpoint: Complete Response Rate at 2 years. Started Sep 2019; status: terminated.
02
Drugs
umbralisib
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT03919175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03919175.